Chabiotech Co.,Ltd.

Equities

A085660

KR7085660009

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
17,100 ^KRW	+0.88%		+1.79%	-12.71%

Jan. 08	CHA Biotech to Partner with Subsidiary to Advance NK Cell Therapy	MT
2023	CHA Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

CHA Biotech Co., Ltd. announced that it has received KRW 44 billion in funding from a group of investors

April 20, 2016

On April 21, 2016, CHA Biotech Co., Ltd. closed the transaction. The fifth series bonds included participation from new investors Kiwoom Securities Co., Ltd., Investment Arm for KRW 9,000,000,000, SBI Savings Bank Inc., Investment Arm for KRW 4,000,000,000, Anda Cruise Private Investment Fund No. 1 for KRW 4,000,000,000, GMB Investment Co., Ltd. for KRW 2,000,000,000, and IBK Capital Corporation for KRW 1,000,000,000.

Latest news about Chabiotech Co.,Ltd.

CHA Biotech to Partner with Subsidiary to Advance NK Cell Therapy	Jan. 08	MT
CHA Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
CHA Biotech : Unit Signs Contract with Sartorius for Viral Vectors Process Technology	21-10-21	MT
CHA Biotech Co., Ltd. announced that it has received KRW 75 billion in funding from a group of investors	20-06-18	CI
CHA Biotech Co., Ltd. announced that it expects to receive KRW 75 billion in funding from a group of investors	20-06-16	CI
Astellas Institute for Regenerative Medicine acquired remaining 50% stake in Stem Cell & Regenerative Medicine International, Inc from CHA Biotech Co., Ltd. for $46.7 million.	19-06-24	CI
Chabiotech To Divest Biotechnology And Medicine And Medical Supplies	18-04-12	CI
Sorrento Therapeutics to Form Joint Venture with CHA Biotech Co	16-08-11	CI
Sorrento Therapeutics, Inc. to Form Joint Venture with CHA Biotech Co., Ltd. to Develop and Commercialize Natural Killer Cell Therapies	16-08-02	CI
CHA Biotech Co., Ltd. announced that it has received KRW 44 billion in funding from a group of investors	16-04-20	CI
CHA Biotech Co., Ltd. announced that it expects to receive KRW 44 billion in funding from Kyunghee Industry Co. Ltd. and other investors	16-04-18	CI
Closed Merger/Acquisition Transaction â€“ Target: Chadiostech Co., Ltd.; Buyer(s): Da Vinci Capital Management Ltd., The European Bank for Reconstruction and Development, Investment Arm; Seller(s): CHA Biotech Co., Ltd., Kyunghee Industry Co. Ltd., Sungkwang Medical Foundation, Endowment Arm; Transaction Size: KRW23503.27 mm	15-12-28	CI
The Da Vinci CIS Private Sector Growth Fund (Fund I), Da Vinci Eurasian Financial Infrastructure Fund (Fund II) and Da Vinci No. 3 Investment Fund (Fund III) of Da Vinci Capital Management Ltd. and The European Bank for Reconstruction and Development, Investment Arm, Chang-Mi Bin, Jung-Seok Oh and Jung-Seok Kang entered into a contract to acquire 22.66% stake in Chadiostech Co., Ltd. from Gwang-Yeol Cha, 8 other individuals, CHA Biotech Co., Ltd., Kyunghee Indus	15-11-29	CI
CHA Healthcare Operation Co., Ltd. cancelled the acquisition of Cha Medical Service Co., Ltd. from CHA Bio&Diostech Inc. and others.	15-11-25	CI
CHA-Meditech Co., Ltd. acquired CHA-BioMed Co. Ltd from CHA Bio&Diostech Inc. and other sellers.	15-06-30	CI
CHA Healthcare Operation Co., Ltd. agreed to acquire Cha Medical Service Co., Ltd. from CHA Bio&Diostech Inc. and others.	14-11-25	CI
CHA Bio & Diostech Co., Ltd. completed the spin-off of camera lens and optical science business division for KRW 140 billion	14-05-01	CI
CHA Bio & Diostech Co., Ltd. agreed to spin-off camera lens and optical science business division.	13-12-25	CI
Cha Bio&Diostech Files Investigational New Drug with Korean FDA for PLX Cells	13-07-08	CI
Pluristem Therapeutics, Inc. Enters into Exclusive License and Commercialization Agreement with CHA Bio & Diostech Co., Ltd	13-06-27	CI
Pluristem Ltd. Enters Strategic Partnership and Licensing Agreement With Cha Bio&Diostech for the Development and Commercialization of PLX Cells for the Treatment of CLI and IC in South Korea	13-06-26	CI

Chart Chabiotech Co.,Ltd.

Duration

Period

More charts

Company Profile

Chabiotech Co.,Ltd. is a Korea-based company mainly engaged in the bio business. Along with its subsidiaries, the Company operates its business through two segments: bio segment and optical segment. Its bio segment engages in the provision of medical services; development of stem cells and cell therapy products; production of cosmetics and cosmetic raw materials; distribution of medical devices and others, as well as cord blood storage, health care services and others. Its optical segment engages in the manufacture of optical lenses, optical modules and other parts, which are used in mobile phone cameras.

Sector

Biotechnology & Medical Research

Calendar

2024-08-08 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CHABIOTECH CO.,LTD.	-12.71%	712M
MODERNA, INC.	+33.63%	50.93B
IQVIA HOLDINGS INC.	-0.09%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-4.96%	29.18B
ICON PUBLIC LIMITED COMPANY	+11.18%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	18.9B
BIO-TECHNE CORPORATION	+8.61%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.73%	12.17B
MEDPACE HOLDINGS, INC.	+28.31%	12.16B

Other Biotechnology & Medical Research